Carboplatin and bevacizumab for recurrent malignant glioma

Maciej Mrugala, Laurie K. Crew, James R. Fink, Alexander M. Spence

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Over 65,000 primary brain tumors are diagnosed annually in the US alone. Malignant gliomas represent more than one-third of such cases. Despite advances in neuroimaging, surgical techniques, radiotherapy and chemotherapy, the survival rate of this disease remains poor. The introduction of agents which disrupt the function of vascular endothelial growth factor (VEGF) and its receptors to glioma therapy has resulted in an unusually high percentage of patients experiencing radiographic responses. Bevacizumab, approved by the Food and Drug Administration for the treatment of recurrent glioblastoma in 2009, has changed the field of neuro-oncology. The drug has been utilized as a single agent and in combination with the classic cytotoxic agents typically applied in this setting. Numerous studies have reported high response rates and encouraging extensions of time-to-progression. The optimal schedule and combination of bevacizumab with alternative drugs has not been identified. The current study presents the results of a retrospective analysis of the combination therapy utilizing bevacizumab with the alkylating agent carboplatin in patients with recurrent malignant glioma.

Original languageEnglish (US)
Pages (from-to)1082-1086
Number of pages5
JournalOncology Letters
Volume4
Issue number5
DOIs
StatePublished - Nov 1 2012
Externally publishedYes

Fingerprint

Carboplatin
Glioma
Vascular Endothelial Growth Factor Receptor
Alkylating Agents
Cytotoxins
United States Food and Drug Administration
Glioblastoma
Neuroimaging
Brain Neoplasms
Pharmaceutical Preparations
Appointments and Schedules
Radiotherapy
Therapeutics
Survival Rate
Drug Therapy
Bevacizumab

Keywords

  • Anti-VEGF therapy
  • Carboplatin
  • Malignant glioma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Carboplatin and bevacizumab for recurrent malignant glioma. / Mrugala, Maciej; Crew, Laurie K.; Fink, James R.; Spence, Alexander M.

In: Oncology Letters, Vol. 4, No. 5, 01.11.2012, p. 1082-1086.

Research output: Contribution to journalArticle

Mrugala, Maciej ; Crew, Laurie K. ; Fink, James R. ; Spence, Alexander M. / Carboplatin and bevacizumab for recurrent malignant glioma. In: Oncology Letters. 2012 ; Vol. 4, No. 5. pp. 1082-1086.
@article{9869a8473a964f0d9f5d494b7ff1b9fa,
title = "Carboplatin and bevacizumab for recurrent malignant glioma",
abstract = "Over 65,000 primary brain tumors are diagnosed annually in the US alone. Malignant gliomas represent more than one-third of such cases. Despite advances in neuroimaging, surgical techniques, radiotherapy and chemotherapy, the survival rate of this disease remains poor. The introduction of agents which disrupt the function of vascular endothelial growth factor (VEGF) and its receptors to glioma therapy has resulted in an unusually high percentage of patients experiencing radiographic responses. Bevacizumab, approved by the Food and Drug Administration for the treatment of recurrent glioblastoma in 2009, has changed the field of neuro-oncology. The drug has been utilized as a single agent and in combination with the classic cytotoxic agents typically applied in this setting. Numerous studies have reported high response rates and encouraging extensions of time-to-progression. The optimal schedule and combination of bevacizumab with alternative drugs has not been identified. The current study presents the results of a retrospective analysis of the combination therapy utilizing bevacizumab with the alkylating agent carboplatin in patients with recurrent malignant glioma.",
keywords = "Anti-VEGF therapy, Carboplatin, Malignant glioma",
author = "Maciej Mrugala and Crew, {Laurie K.} and Fink, {James R.} and Spence, {Alexander M.}",
year = "2012",
month = "11",
day = "1",
doi = "10.3892/ol.2012.839",
language = "English (US)",
volume = "4",
pages = "1082--1086",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Carboplatin and bevacizumab for recurrent malignant glioma

AU - Mrugala, Maciej

AU - Crew, Laurie K.

AU - Fink, James R.

AU - Spence, Alexander M.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Over 65,000 primary brain tumors are diagnosed annually in the US alone. Malignant gliomas represent more than one-third of such cases. Despite advances in neuroimaging, surgical techniques, radiotherapy and chemotherapy, the survival rate of this disease remains poor. The introduction of agents which disrupt the function of vascular endothelial growth factor (VEGF) and its receptors to glioma therapy has resulted in an unusually high percentage of patients experiencing radiographic responses. Bevacizumab, approved by the Food and Drug Administration for the treatment of recurrent glioblastoma in 2009, has changed the field of neuro-oncology. The drug has been utilized as a single agent and in combination with the classic cytotoxic agents typically applied in this setting. Numerous studies have reported high response rates and encouraging extensions of time-to-progression. The optimal schedule and combination of bevacizumab with alternative drugs has not been identified. The current study presents the results of a retrospective analysis of the combination therapy utilizing bevacizumab with the alkylating agent carboplatin in patients with recurrent malignant glioma.

AB - Over 65,000 primary brain tumors are diagnosed annually in the US alone. Malignant gliomas represent more than one-third of such cases. Despite advances in neuroimaging, surgical techniques, radiotherapy and chemotherapy, the survival rate of this disease remains poor. The introduction of agents which disrupt the function of vascular endothelial growth factor (VEGF) and its receptors to glioma therapy has resulted in an unusually high percentage of patients experiencing radiographic responses. Bevacizumab, approved by the Food and Drug Administration for the treatment of recurrent glioblastoma in 2009, has changed the field of neuro-oncology. The drug has been utilized as a single agent and in combination with the classic cytotoxic agents typically applied in this setting. Numerous studies have reported high response rates and encouraging extensions of time-to-progression. The optimal schedule and combination of bevacizumab with alternative drugs has not been identified. The current study presents the results of a retrospective analysis of the combination therapy utilizing bevacizumab with the alkylating agent carboplatin in patients with recurrent malignant glioma.

KW - Anti-VEGF therapy

KW - Carboplatin

KW - Malignant glioma

UR - http://www.scopus.com/inward/record.url?scp=84866100889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866100889&partnerID=8YFLogxK

U2 - 10.3892/ol.2012.839

DO - 10.3892/ol.2012.839

M3 - Article

AN - SCOPUS:84866100889

VL - 4

SP - 1082

EP - 1086

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 5

ER -